New Thermal Neutron Capture Therapy for Malignant Melanoma: Melanogenesis‐Seeking 10B Molecule‐Melanoma Cell Interaction From In Vitro to First Clinical Trial

Mishima, Yutaka; Ichihashi, Masamitsu; Hatta, Susumu; Honda, C.; Yamamura, Keizo; Nakagawa, Toshio

doi:10.1111/j.1600-0749.1989.tb00196.x

Cited by 125 publications

(53 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other than patients with primary brain tumors, the second largest group that has been treated by BNCT were those with cutaneous melanomas. Mishima et al previously had carried out extensive studies in experimental animals with either primary or transplantable melanomas using 10 B-enriched BPA as the capture agent (175,176). The use of BPA was based on the premise that it would be selectively taken up by and accumulate in neoplastic cells that were actively synthesizing melanin (177).…”

Section: Clinical Studies Of Boron Neutron Capture Therapy For Othertmentioning

confidence: 99%

Boron Neutron Capture Therapy of Cancer: Current Status and Future Prospects

Barth

Coderre²,

Vicente³

et al. 2005

Clinical Cancer Research

891

651

View full text Add to dashboard Cite

Background: Boron neutron capture therapy (BNCT) is based on the nuclear reaction that occurs when boron-10 is irradiated with low-energy thermal neutrons to yield high linear energy transfer A particles and recoiling lithium-7 nuclei. Clinical interest in BNCT has focused primarily on the treatment of high-grade gliomas and either cutaneous primaries or cerebral metastases of melanoma, most recently, head and neck and liver cancer. Neutron sources for BNCT currently are limited to nuclear reactors and these are available in the United States, Japan, several European countries, and Argentina. Accelerators also can be used to produce epithermal neutrons and these are being developed in several countries, but none are currently being used for BNCT. Boron Delivery Agents: Two boron drugs have been used clinically, sodium borocaptate (Na 2 B 12 H 11 SH) and a dihydroxyboryl derivative of phenylalanine called boronophenylalanine. The major challenge in the development of boron delivery agents has been the requirement for selective tumor targeting to achieve boron concentrations (f20 Ag/g tumor) sufficient to deliver therapeutic doses of radiation to the tumor with minimal normal tissue toxicity. Over the past 20 years, other classes of boron-containing compounds have been designed and synthesized that include boroncontaining amino acids, biochemical precursors of nucleic acids, DNA-binding molecules, and porphyrin derivatives. High molecular weight delivery agents include monoclonal antibodies and their fragments, which can recognize a tumor-associated epitope, such as epidermal growth factor, and liposomes. However, it is unlikely that any single agent will target all or even most of the tumor cells, and most likely, combinations of agents will be required and their delivery will have to be optimized. Clinical Trials: Current or recently completed clinical trials have been carried out inJapan, Europe, and the United States. The vast majority of patients have had high-grade gliomas. Treatment has consisted first of ''debulking'' surgery to remove as much of the tumor as possible, followed by BNCTat varying times after surgery. Sodium borocaptate and boronophenylalanine administered i.v have been used as the boron delivery agents. The best survival data from these studies are at least comparable with those obtained by current standard therapy for glioblastoma multiforme, and the safety of the procedure has been established. Conclusions: Critical issues that must be addressed include the need for more selective and effective boron delivery agents, the development of methods to provide semiquantitative estimates of tumor boron content before treatment, improvements in clinical implementation of BNCT, and a need for randomized clinical trials with an unequivocal demonstration of therapeutic efficacy. If these issues are adequately addressed, then BNCTcould move forward as a treatment modality.

show abstract

Section: Clinical Studies Of Boron Neutron Capture Therapy For Othertmentioning

confidence: 99%

Boron Neutron Capture Therapy of Cancer: Current Status and Future Prospects

Barth

Coderre²,

Vicente³

et al. 2005

Clinical Cancer Research

891

651

View full text Add to dashboard Cite

show abstract

“…Better "B-containing substances have now been developed and promising approaches have recently been reported for the treatment of both malignant gliomas ( 5-9) and melanomas (10). The strategies for developing new boron-containing substances have been reviewed ( 1 I , 12) and were recently discussed at an international workshop held in Uppsala in May 1991.…”

Section: Historymentioning

confidence: 99%

“…2b). Promising BNCT studies on experimental animals have been reported ( 10,53) and the first clinical trial with BPA was performed by Mishima (10,36,54). The first patient suffered from an inoperable malignant melanoma lesion on the left occiput and the perilesional injections of BPA, followed by irradiation with thermal neutrons, was successfully tested.…”

Section: Boron-containing Substancesmentioning

confidence: 99%

See 1 more Smart Citation

Present Status of Boron Neutron Capture Therapy

1992

View full text Add to dashboard Cite

“…9)11) It exhibits two crystal structures, orthorhombic and hexagonal, which differ significantly in coordination number, lattice volume, etc. While orthorhombic GdF 3 (space group Pnma) is thermodynamically stable at room temperature as shown in Table 1, there are very few studies on unstable hexagonal GdF 3 (space group p3-c1).…”

Section: Introductionmentioning

confidence: 99%

Influence of changes in crystal structures on the luminescent characteristics of GdF3:Tm3+ in a phase separation glass

Jin

Ochiishi

Shibuya

et al. 2018

J. Ceram. Soc. Japan

View full text Add to dashboard Cite

Hexagonal GdF 3 :Tm 3+ , which is thermodynamically unstable at room temperature, was successfully crystallized in borosilicate glass using a phase separation technique. The crystal structure of GdF 3 was controlled by the addition of alkaline earth metals to the glass composition. Increasing the amount of SrF 2 added to the glass composition to 1.65 mol % increased the amount of precipitation of hexagonal GdF 3 :Tm 3+ crystals and the luminescence intensity. Lanthanide trifluoride phosphors were restrictively obtained in the borate phase as a result, and the emission of Tm 3+ at 458 nm was observed. Furthermore, the luminescence intensity of GdF 3 :Tm 3+ in the phase separation glass upon SrF 2 -doping was about three times larger than that without doping.

show abstract

New Thermal Neutron Capture Therapy for Malignant Melanoma: Melanogenesis‐Seeking ¹⁰B Molecule‐Melanoma Cell Interaction From In Vitro to First Clinical Trial

Cited by 125 publications

References 6 publications

Boron Neutron Capture Therapy of Cancer: Current Status and Future Prospects

Boron Neutron Capture Therapy of Cancer: Current Status and Future Prospects

Present Status of Boron Neutron Capture Therapy

Influence of changes in crystal structures on the luminescent characteristics of GdF<sub>3</sub>:Tm<sup>3+</sup> in a phase separation glass

Contact Info

Product

Resources

About